Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-γ agonist use in prediabetes

被引:10
|
作者
Kavanagh, Kylie [1 ]
Brown, Kathleen K. [2 ]
Berquist, Mandy L. [2 ]
Zhang, Li [1 ]
Wagner, Janice D. [1 ]
机构
[1] Wake Forest Univ, Comparat Med Sect, Dept Pathol, Sch Med, Winston Salem, NC 27127 USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2010年 / 59卷 / 06期
基金
美国国家卫生研究院;
关键词
LOWERS BLOOD-PRESSURE; PPAR-GAMMA; INSULIN SENSITIVITY; FAT DISTRIBUTION; BODY-WATER; ROSIGLITAZONE; RETENTION; VOLUME; THIAZOLIDINEDIONES; EXPRESSION;
D O I
10.1016/j.metabol.2010.02.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pioglitazone is prescribed to improve insulin sensitivity in type 2 diabetes mellitus patients and has been discussed as a therapy for metabolic syndrome. Pioglitazone and other thiazolidinediones are associated with fluid retention and edema that may exacerbate existing or developing congestive heart failure, which is often present in these patients. Using a nonhuman primate model, our aims were to evaluate (1) whether fluid shifts were detectable in normoglycemic monkeys, (2) which fluid compartment changed, and (3) whether fluid retention was dose dependent. Seventeen adult male cynomolgus macaques (Macaca fascicularis) were studied in a Latin square design such that all animals received 0, 1, 2, and 5 mg/kg pioglitazone for 6 weeks with 2 weeks of washout between dosing intervals. Doses approximated human exposures achieved with 30, 45, and 60 mg. At the end of each period, animals were weighed and underwent dual-absorption x-ray absorption scanning for body composition measurements. Fluid volumes were quantitated by Evans blue dilution for plasma volume, equilibration of sodium bromide for extracellular water, and deuterated water for total body water. Significant (P < .05) effects were seen with expansion of PV at both the 2- and 5-mg/kg doses, along with reduced plasma sodium at 5 mg/kg; however, surrogate end points used to indicate fluid retention (body weight, hematocrit, total protein, and albumin) did not change significantly. Significant trends toward increases in interstitial fluid and extracellular water with increasing dose were apparent. Pioglitazone effectively improved metabolic status by significantly decreasing fasting glucose and triglycerides and increasing adiponectin. We conclude that thiazolidinedione-related plasma volume expansion occurs in nondiabetic primates and that fluid retention is detectable when compartments are directly measured. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:914 / 920
页数:7
相关论文
共 50 条
  • [21] Effects of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
    Suzuki, Shugo
    Arnold, Lora L.
    Pennington, Karen L.
    Kakiuchi-Kiyota, Satoko
    Wei, Min
    Wanibuchi, Hideki
    Cohen, Samuel M.
    [J]. TOXICOLOGICAL SCIENCES, 2010, 113 (02) : 349 - 357
  • [22] Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
    X. Sun
    R. Han
    Z. Wang
    Y. Chen
    [J]. Diabetologia, 2006, 49 : 1303 - 1310
  • [23] Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice
    Ying Zhang
    Jin Wang
    Qiao-dan Zhou
    Cong-hui Zhang
    Qing Li
    Shuai Huang
    Juan Zhan
    Kun Wang
    Yan-yan Liu
    Gang Xu
    [J]. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36 : 41 - 47
  • [24] Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice
    Zhang, Ying
    Wang, Jin
    Zhou, Qiao-dan
    Zhang, Cong-hui
    Li, Qing
    Huang, Shuai
    Zhan, Juan
    Wang, Kun
    Liu, Yan-yan
    Xu, Gang
    [J]. JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2016, 36 (01) : 41 - 47
  • [25] Peroxisome Proliferator-activated Receptor-γ Agonist Pioglitazone Fails to Attenuate Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
    张颖
    王瑾
    周巧丹
    章从惠
    李青
    黄帅
    詹娟
    王堃
    刘颜颜
    徐钢
    [J]. Current Medical Science, 2016, (01) : 41 - 47
  • [26] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders
    Honda, Tsuyoshi
    Kaikita, Koichi
    Tsujita, Kenichi
    Hayasaki, Takanori
    Matsukawa, Masakazu
    Fuchigami, Shunichiro
    Sugiyama, Seigo
    Sakashita, Naomi
    Ogawa, Hisao
    Takeya, Motohiro
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 44 (05) : 915 - 926
  • [27] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction
    Shiomi, T
    Tsutsui, H
    Hayashidani, S
    Suematsu, N
    Ikeuchi, M
    Wen, J
    Ishibashi, M
    Kubota, T
    Egashira, K
    Takeshita, A
    [J]. CIRCULATION, 2002, 106 (24) : 3126 - 3132
  • [28] Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-γ agonist
    Aleo, MD
    Lundeen, GR
    Blackwell, DK
    Smith, WM
    Coleman, GL
    Stadnicki, SW
    Kluwe, WM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03): : 1173 - 1182
  • [29] Pioglitazone, a Ligand for Peroxisome Proliferator-activated Receptor-γ Acts as an Inhibitor of Colon Cancer Liver Metastasis
    Takano, Shota
    Kubota, Tetsuro
    Nishibori, Hideki
    Hasegawa, Hirotoshi
    Ishii, Yoshiyuki
    Nitori, Nobuhiro
    Ochiai, Hiroki
    Okabayashi, Koji
    Kitagawa, Yuko
    Watanabe, Masahiko
    Kitajima, Masaki
    [J]. ANTICANCER RESEARCH, 2008, 28 (6A) : 3593 - 3599
  • [30] The Role of Peroxisome Proliferator-Activated Receptor-γ PPARγ) in Alzheimer’s DiseaseTherapeutic Implications
    Qingguang Jiang
    Michael Heneka
    Gary E. Landreth
    [J]. CNS Drugs, 2008, 22 : 1 - 14